Can you specify teflaro's patent expiry year for abbvie?

Teflaro Patent Expiry for AbbVie

Teflaro, also known as ceftaroline, is a cephalosporin antibiotic developed by Celarion, but distributed in the United States by AbbVie through a licensing agreement.

However, the drug's patent status can be a bit more complex. According to DrugPatentWatch.com, the original patent for teflaro, assigned to Celarent Pharmaceuticals, expired in 2019. The patent was initially set to expire in 2021 but was challenged and adjusted.

AbbVie's Role and Patent Situation

AbbVie currently markets and distributes teflaro under an agreement with Celarion, but as the owner of the patent, it was originally Celarent Pharmaceuticals that developed it. The original patent (US8,414,155) for Teflaro expired in July 2021.

However, this is not to be confused with other patents covering Teflaro, which have different expiry dates. There are patents covering certain aspects of the drug or variations, which may have different expiry dates.

As such, the patent landscape around Teflaro is complex and constantly evolving.



Sources:

1. DrugPatentWatch.com
2. AbbVie's official website for Teflaro